Acta Scientific Ophthalmology (ASOP)

Case Report Volume 3 Issue 3

Thyroid Eye Disease (Ted) Management: A Case Report

Bashir Alnajjar*

Ophthalmology, Surger, Seha Abodhabi, UAE

*Corresponding Author: Bashir Alnajjar,Ophthalmology, Surger, Seha Abodhabi, UAE.

Received: January 31, 2020; Published: February 27, 2020


  Thyroid eye disease (TED) is seen most commonly with Graves’ disease Symptoms include diplopia, eyelid erythema and retraction, and soreness and grittiness of eyes with increased watering. Severe cases (3 - 5%) may present with pain, corneal ulceration, optic nerve compression and partial/total loss of vision.

  Corticosteroids are the primary treatment for active phase TED, although there is risk of adverse effects such as weight gain, hypertension and immunosuppression with long-term, high-dose use.

  We will discuss a patient history with TED before, during and after treatment with tocilizumab and steroids Tocilizumab is current treatment options for moderate-to-severe.

  Given the role in the pathogenesis of TED of interleukin (IL)-6 expression in adipocytes, fibroblasts and macrophages, the proposed theory is that inhibition of IL-6 by tocilizumab may be an effective treatment in TED by directly reducing the inflammatory response.

Keywords: Thyroid; Eye Disease



  1. The  European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the  (2016).
  2. Graves’ ophthalmopathy. N Engl J Med
  3. publication/41562276_Graves'_ophthalmopathy_N_Engl_J_-Med-Clinical Response to -Tocilizumab in Severe Thyroid Eye Disease
  4. publication/303893349_Clinical_Response_to_Tocilizumab_in_Severe_Thyroid_Eye_Disease




Citation: Bashir Alnajjar. “Thyroid Eye Disease (Ted) Management: A Case Report”. Acta Scientific Ophthalmology 3.2 (2020): 40-44.


Acceptance rate35%
Acceptance to publication20-30 days
ISI- IF1.042
JCR- IF0.24

Indexed In

News and Events

Contact US